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Background: The hyper-reactive malarial splenomegaly syndrome (HMS) is a leading cause of massive splenomegaly
in malaria-endemic countries. HMS is caused by a chronic antigenic stimulation derived from the malaria parasite.
Classic Fakunle’s major criteria for case definition are: persistent gross splenomegaly, elevated anti-malarial antibodies,
IgM titre >2 SD above the local mean value and favourable response to long-term malaria prophylaxis. The syndrome is
fatal if left untreated. The aim of this study is to systematically review the literature about HMS, particularly focussing on
case definition, epidemiology and management.
Methods: The search strategy was based on the following database sources: Pubmed, EmBase, Scopus. Search was
done in March, 2014 and limited to English, Spanish, Italian, French, and Portuguese.
Results: Papers detected were 149, of which 89 were included. Splenomegaly was variably defined and the criterion
of increased IgM was not always respected. The highest prevalence was reported in Papua New Guinea (up to 80%).
In different African countries, 31 to 76% of all splenomegalies were caused by HMS. Fatality rate reached 36% in three
years. The most frequent anti-malarial treatments administered were weekly chloroquine or daily proguanil from a
minimum of one month to lifelong. In non-endemic countries, a few authors opted for a single, short anti-malarial
treatment. All treated patients with no further exposure improved. Cases not completely fulfilling Fakunle’s criteria and
therefore untreated, subsequently evolved into HMS. It seems thus appropriate to treat incomplete or ‘early’ HMS, too.
Conclusions: For patients not re-exposed to endemic areas, a short course of treatment is sufficient, showing that
eradicating the infection is sufficient to cure HMS. Longer (probably lifelong) courses, or intermittent treatments, are
required for those who remain exposed. Splenectomy, associated with high mortality, should be strictly limited to cases
not responding to medical treatment.
Keywords: Hyper-reactive, Malarial, Splenomegaly, Management, Treatment, Epidemiology, ReviewBackground
Hyper-reactive malarial splenomegaly (HMS) represents
one of the leading causes of massive splenomegaly in
malaria-endemic countries [1]. HMS is caused by an ab-
errant immune response to a chronic antigenic stimula-
tion in subjects long exposed to malaria parasites [2].
Previously defined as tropical splenomegaly syndrome
(TSS), HMS has long been considered distinct from a
splenomegaly directly resulting from malarial parasit-
aemia. The syndrome is characterized by macroglobulinae-
mia with overproduction of immunoglobulin, especially of
the IgM class, which aggregate into high molecular* Correspondence: zeno.bisoffi@sacrocuore.it
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unless otherwise stated.immune complexes and cause persistent splenomegaly be-
cause of prolonged clearance from the reticuloendothelial
tissue [3]. Cryoglobulins and autoantibodies, such as, for
instance, rheumatoid factor, contribute to the macroglobu-
linaemia [4]. A direct correlation between the spleen size
and the IgM titre has been described [5-8]. Genetic factors
are likely to be involved in the development of HMS.
Studies carried out in Papua New Guinea reported a
higher incidence in individuals with HLA-DR2 haplotype
or with HLA heterozygosity [9,10]. Moreover a retrospect-
ive study carried out in Ghana evidenced that the relatives
of patients with HMS were more likely to have spleno-
megaly than population controls [11].
Diagnostic criteria for HMS were proposed by Fakunle in
1981 [12]. Major criteria are: persistent gross splenomegalyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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out any other apparent cause, elevated anti-malarial anti-
bodies, IgM titre >2 standard deviations (SD) above the
local mean value and favourable clinical and immunological
response to long-term malaria prophylaxis [13]. Minor
diagnostic criteria are: hepatic sinusoidal lymphocytosis,
normal cellular and humoral immune responses to anti-
genic challenge, including phytohaemagglutinin stimulation
(PHA), hypersplenism, lymphocyte proliferation, occur-
rence within families or tribes.
Other laboratory findings are related to hypersplenism,
such as variable degrees of pancytopaenia, especially an-
aemia. The underlying mechanism causing anaemia is
the plasma volume expansion and the spleen sequestration
along with an increased haemolysis. Reticulocytes and in-
direct bilirubin are often increased [14,15]. Acute episodes
of haemolysis can also occur and seem to be associated
with an autoimmune, cold-agglutinin-mediated response
triggered by non-patent parasitaemia [16]. Sinusoidal lym-
phocytosis may be revealed by histologic examination of
liver biopsy, but it is not specific. The peripheral blood
smear in HMS subjects is most often negative. However,
using more sensitive diagnostic methods, such as polymer-
ase chain reaction (PCR), the proportion of positive cases
increases [17-19].
The main, severe complications of HMS are acute in-
fectious illnesses, haemolytic anaemia (especially during
pregnancy) and splenic rupture. According to historical
data, the syndrome is often fatal if left untreated [20].
Some authors have hypothesized that HMS could be
considered as a pre-malignant state that could evolve to
chronic lymphocytic or hairy cell leukaemia or splenic
lymphoma with villous lymphocytes, as a result of a
multi-step process with a single clone selection in a set
of deregulated polyclonal expansion of lymphocytes
[21-23]. Actually, HMS and lymphoproliferative disor-
ders are often clinically indistinguishable. Serological
similarities between HMS and splenic lymphoma with
villous lymphocytes (SLVL) have also been reported. In
the latter condition, too, a markedly raised anti-
malarial antibody and IgM level have been observed
[24]. Spleen reduction after a prolonged anti-malarial
treatment is one of the main criteria used to diagnose
HMS. Failure to respond makes an alternative diagno-
sis more likely [25].
Despite a comparatively large amount of literature on
malaria, only a few papers deal with this particular com-
plication. Moreover, diagnostic criteria are not uniform,
epidemiological data are scarce and the clinical manage-
ment has been variable. This aim of this review was to
retrieve the relevant literature on HMS, focusing in par-
ticular on three key aspects: diagnostic criteria for the
case definition, epidemiology (prevalence and mortality)
and management.Methods
Searching
The search strategy was based on the following database
sources: Pubmed, EmBase, Scopus, with no limitation as
for the year of publication. The oldest paper retrieved
was published in 1966. Our searching strategy was based
on these keywords (using of course the specific language of
each database): asymptomatic malaria, chronic malaria,
malarious splenomegaly, splenomegaly syndrome, spleno-
megalic syndrome, tropical splenomegaly, malarial spleno-
megaly. Additional search terms used were: epidemiology,
prevalence, incidence, pathogenesis, diagnosis, case defin-
ition, prognosis, mortality, fatality, management, treatment.
The search was restricted to ‘humans’ and to the fol-
lowing languages: English, French, Spanish, Italian, and
Portuguese. The search was carried out in March 2014.
Reference lists of all the articles identified were also ex-
amined and relevant cited references were reviewed
similarly.
Types of study
Surveys, epidemiological studies, case reports/series,
studies on etiology, pathogenesis, diagnosis and treat-
ment of HMS were collected. Reviews were excluded
from the analysis.
Inclusion criteria
Articles had to deal with hyperactive malaria splenomeg-
aly or its synonymous, such as tropical splenomegaly or
chronic malaria, as a main subject.
Exclusion criteria
Papers were excluded when primarily dealing with acute
malaria or with other causes of splenomegaly (such as
EBV, CMV, HIV, schistosomiasis). All papers identified
were assessed by two reviewers (SL and DB) who inde-
pendently screened the titles and abstracts, using the cri-
teria mentioned above. Then they read the full text of
those retained after the first screening. In case of differ-
ences, a final consensus was reached after discussion
that included a third reviewer (ZB).
Data were extracted from all finally retained papers
and specific fields of an Excel spreadsheet were popu-
lated. The spreadsheet was previously created on the
basis of the study’s purpose. With available data the ana-
lysis was focused first on epidemiology, such as gender
and age of patients, country where the study was con-
ducted and country of origin of the patients, prevalence
of the syndrome in a given area, mortality rate, etc. Then
we filled the section on diagnostic criteria and in par-
ticular if they followed the Fakunle’s criteria or not. Fi-
nally data were extracted considering the type and
duration of the treatment and when available, also data
on outcome at follow-up. Finally, the reported treatment
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was summarized. The studies were obviously heteroge-
neous but, because of the extreme poverty of papers
dealing with HMS, it was aimed to provide the most
comprehensive picture of the main reported aspects of
the syndrome since the first publication until now.
Results
The electronic search identified 331 papers from
Pubmed, 60 From EmBase and 75 from Scopus. Sixty-
eight duplicates were discarded. After an evaluation of
language, titles and abstracts, a total of 152 papers were
detected that may relate to this review. Thirteen were
not retrieved. On the basis of the full text, 51 papers
were discarded since they did not deal with HMS.
The remaining 89 papers were included. The flow is
summarized in Figure 1 (PRISMA flow chart).Figure 1 PRISMA flow chart.Sixty-three papers described cases observed or studies
conducted in endemic areas. In particular, 50/63 (80%)
in Africa, 8/63 (12%) in Asia [26-33], and 5/63 (8%) in
South America [16,34-37]. Of the 26 papers from non-
endemic countries, 22 (85%) concerned patients ob-
served in Europe, the others were case reports from
Israel [38], the USA [39,40] and Hong Kong [41]. Apart
from two retrospective studies [42,43] and one prospect-
ive longitudinal study [19], the other papers were case
reports/case series. These included immigrants (15 pa-
pers), expatriates (ten papers) or both groups (one
paper). The range of age of subjects under study fell
from birth [44] to a maximum of 77 years [45] and most
of the patients with HMS were young adults. According
to some studies a male gender prevalence was noted but
analysing the literature no significant gender difference
was observed.
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Fakunle’s criteria were mostly used, but adherence to
them was variable. Most authors declaring to follow
Fakunle’s criteria considered as splenomegalic a patient
with spleen size bigger than 10 cm below the costal mar-
gin (Figure 2), but lower measures were also reported
[34,46]. Overall, the range of the spleen size reported to
define splenomegaly was extremely variable, from 3 [27]
to 30 cm [47] below the costal margin. Both palpatory
and echographic methods were used. Some authors pre-
ferred to use Hackett’s spleen size classification
[16,20,29,35,48-50], which is based on palpation. They
considered as splenomegalic a patient with spleen size
classified at least in the II or III grade (Table 1). Other
authors did not define splenomegaly, but described the
spleen as “gross” [13] or “huge” [39]. The increase in
IgM titre was not always respected. Some authors con-
sidered it neither specific nor necessary [51,52]. In five
studies the syndrome was also diagnosed in absence of
raised IgM [1,32,37,52,53].
In other studies the case definition relied on at least two
out of the three major criteria (leaving aside anti-malarial
antibody titre that is invariably raised), besides excluding
other causes of splenomegaly [28,42,43,54]. It was observed
that some of those patients, if further exposed to malaria,
evolved to the complete syndrome, and this suggested the
possibility to make the diagnosis at an early stage [43].
Moreover, a direct correlation between the splenomegaly
class and the IgM level has been demonstrated, suggesting
a continuum in the syndrome evolution [42].
Another approach to the diagnosis of HMS was a
combination of major and minor criteria. In 1976, beforeFigure 2 African patient with splenomegaly seen at the Centre for Tropicathe publication of Fakunle’s criteria, Mardsen and Crane
had suggested the following: persistent splenomegaly,
hepatic sinusoidal lymphocytosis, disproportionate eleva-
tion of serum IgM levels and high anti-malarial antibody
titre, without considering the response to the therapy [55].
In other papers, the exclusion of other causes of spleno-
megaly in an endemic area was sufficient to consider a
patient as affected by HMS [56,57].
Epidemiology in endemic countries
There are scanty data regarding the prevalence of the
syndrome in the general population. Studies performed
in Papua New Guinea reported an extraordinarily high
prevalence of the syndrome (85% in five years old chil-
dren and 80% in adults) among inhabitants of the Upper
Watut Valley [58]. The relationship between the parasite
rate and the spleen size varied with age: in children the
spleen size appeared to be directly related to the parasite
rate, while in adults the opposite occurred [44].
Studies conducted in The Gambia reported a much
lower prevalence: 1.6 per 1,000 subjects aged ten years
or older [44,59]. Other authors studied the proportion of
splenomegaly caused by HMS. In northern Nigeria, 30
splenomegalic patients out of 75 (40%) were classified as
having HMS, and so were 137 out of 334 subjects in
northern Zambia (again, 40%), 38 patients out of 131
(31%) in Kenya, 91/221 (41%) in Ghana and 87/114
(76%) in eastern Sudan [1,48,60-62].
In Papua New Guinea, the overall mortality rate in a
series of 75 untreated patients during a 72-month period
was 36%, reaching 57% in patients with grade V spleno-
megaly [20]. In another study, the reported mortalityl Diseases, Negrar.
Table 1 Hackett’s spleen size classification
Spleen grade Description of the spleen grade
0. Spleen not palpable even on deep inspiration.
I. Spleen palpable below costal margin, usually on
deep inspiration.
II. Spleen palpable, but not beyond a horizontal line halfway
between the costal margin and umbilicus, measured in a
line dropped vertically from the left nipple.
III. Spleen palpable more than halfway to umbilicus, but
not below a line horizontally running through it.
IV. Palpable below umbilicus but not below a horizontal
line halfway between umbilicus and pubic symphysis.
V. Extending lower than class 4.
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to 13% in subjects under chloroquine prophylaxis [2].
The main causes of death were infectious diseases, acute
haemolysis and multi-organ failure (MOF) [35,63,64].
Non-endemic countries
The first case of HMS in a Caucasian who lived in Africa
was described in 1970 [65]. Only two case series were
retrieved describing more than ten expatriates returning
to Europe [42,43]. Most patients had lived for at least
five years in an endemic area. Both series (in Belgium
and Italy, respectively) included patients fully responding
to the classic criteria (17/49 and 29/57, respectively) and
patients with an incomplete syndrome. The clinical out-
come at follow-up was favourable for all patients who
remained in Europe and presented at follow-up. The only
other case series described in Europe is a prospective
study in Spain [19] on 14 immigrants (from Equatorial
Guinea or Cameroon), all responded to Fakunle’s criteria.
Four had a positive blood film, and four additional
patients were positive at PCR.
A six years old child was the youngest immigrant from
Africa diagnosed with HMS [66]. A seven years old child,
born in UK to Ghanaian parents, was diagnosed with
HMS after three short trips to Ghana (eight weeks in
total), the last one eight months before presentation. Des-
pite the absence of fever or fever history, Plasmodium
falciparum trophozoites and gametocytes were found in
her blood [67].
Therapy in endemic countries
The most frequent anti-malarial treatments adminis-
tered in endemic countries were weekly chloroquine
[2,26,31-34,37,49,61,62,68-71] or daily proguanil [13,25,
52,57,60,64,71-78]. Other regimens were chloroquine
plus primaquine [27,70], mefloquine [28], quinine [18],
pyrimethamine [56], artemether [18], and sulphadoxine/
pyrimethamine [18,50]. Overall, the duration of therapy
ranged from a minimum of one month [13,56] to a life-
long treatment [2]. The largest cohort of patients (148)under lifelong chloroquine prophylaxis showed an im-
provement of all, with a partial regression of splenomegaly
and an increase of haemoglobin level over a period of 12-
18 months. However, in no case a normalization of the
spleen size was observed. The prophylactic regimen halved
the mortality rate over ten years compared to untreated
patients [79]. Other studies confirmed the efficacy of this
regimen [27,31,71]. The most recent one was carried out
in Sudan in 2013 and reported, after a three-month ther-
apy, a complete normalization of the spleen size in 14 pa-
tients out of 21 [69]. In Nigeria, 10/39 subjects fully
recovered and 29/39 improved after daily proguanil ad-
ministered for two to 12 months [76].
Two papers reported improvement after a single, short
course of anti-malarial treatment followed by oral ster-
oid therapy [50,80]. However, other authors observed
that the syndrome tended to quickly relapse once anti-
malarial therapy was stopped [75,78]. Only one study in
Sudan [18] opted (for the 33 patients included) for a
short course anti-malarial treatment (various regimens)
as for an acute falciparum malaria. For most of the pa-
tients, other treatments were administered during the
follow-up (for 15 to 24 months). However, no prophy-
laxis was administered during the different treatments.
Thirty-six patients had improved and 12 had worsened
at the end of the follow-up period, while six were re-
ported as unchanged. Table 2 summarizes the main re-
sults of the studies including more than ten patients.
Only few data are available on HMS treatment in
pregnancy. A recent retrospective study carried out in
Thailand reported the efficacy of weekly mefloquine, ad-
ministered for two to 25 weeks (median nine weeks) to
31 pregnant women with suspected HMS, without any
major adverse event. Those presenting only one or two
major criteria of the conventional definition of HMS
were also treated and showed on average a spleen size
reduction of more than 40% [28].
Therapy in non-endemic countries
The management of HMS in non-endemic areas has
been heterogeneous. Overall, the drugs used were:
chloroquine, quinine plus clindamycin or doxycycline
or pyrimethamine-sulphadoxine, proguanil, mefloquine,
atovaquone-proguanil, halofantrine, and artemisinin de-
rivatives. A few authors preferred to prescribe a short
course (≤seven days) of anti-malarial treatment, while
the majority opted for longer therapy. Overall, the
follow-up period ranged from six weeks to 36 months.
In six studies out of 21 a short course of treatment (as
for an acute malaria episode) was administered
[17,42,43,66,81,82]. In the Belgian study (Table 3) [42]
all 49 expatriates received a short course of anti-
malarial therapy. Thirty-nine patients were followed up
for at least two weeks after treatment (median six
Table 2 Treatment outcome: studies conducted in malaria endemic countries with >10 patients and follow up data available
Study Country N patients Type of treatment Duration Follow up Outcome
Pryor 1967 [49] New Guinea 99 CLQ 1500 mg/3 days, then 300 mg/wk NR average 4.1 mths in hospital
plus 6-23 mths out
No change in spleen size,
general benefit
Sagoe 1970 [57] Nigeria 43 PG 100 mg/day ≥6 mths 6 mths 32 improved 11 worsened
Bagshawe 1970 [13] Kenya 28 PG 100 mg/day 1 - 26 mths 1 -6 mths 16 improved 11 worsened 8
unchanged
Stuvier et al. 1971 [27] India 14 PQ 15 days, then CLQ 300 mg/wk 6-14 mths once/mths for ≥6 mths 11/14 spleen size ↓50%
Stuvier et al. 1974 [71] Uganda 41 CLQ 300 mg/wk or PG 100 mg/day NR 4- 20 mths all improved
Bryceson et al. 1976 [60] North Nigeria 30 PG 100 mg/day 3 - 12 mths 3 mths 12/13 improved (17 lost)
Fakunle and Greenwood 1980 [64] Nigeria 69 PG 100 mg/day 3 mths 10 wks 2 /40 died plus 8/29 defaulters
De Cock et al. 1986 [52] Kenya 38 PG 100 mg/day or CLQ 300 mg/wk NR NR 13/18 improved (20 lost)
Crane 1986 [2] Papua NG 148 CLQ 300 mg/wk lifelong 12-18 mths 146 improved (2 lost)
Gupta et al. 1987 [31] India 54 CLQ 300 mg, 1 or 2/wk 2 yrs 2 yrs 54 Improved
Mac Onuigbo and Mbah 1992 [76] Nigeria 39 PG 100 or 200 mg 2 - 12 mths 2 - 12 mths All improved (10 cured)
Manenti et al. 1994 [79] Tanzania 312 PMT 25 mg/wk 1 mths 3 mths 208 improved 104 unchanged
A-Elgayoum et al. 2011 [18] Sudan 54 Single short term treatment
(various regimens)
1 d to 1 wk (often repeated) 15 –24 mths 36 improved 12 worsened 6
unchanged
Alkadarow et al. 2013 [69] Sudan 33 CLQ 300 mg/wk 3 mths 3 mths 14/21 improved (12 lost)









Table 3 Treatment outcome: studies conducted in non endemic countries with >10 patients and follow up data available
Study Country N patients Treatment Duration Follow up Outcome
Van den Ende et al. 2000 [42] Belgium 39 Caucasians, 17 fully responding
to Fakunle criteria
Single, short term treat for Pf
malaria (various regimens)
1 day to 1 week according
to drug
≥2 wks (average 6 wks) All not re-exposed improved
or fully recovered
Eseme et al. 2004 [43] Italy 49 Caucasians (29 fully responding
to Fakunle criteria) plus 8 Africans
(different countries)
Single, short term treatment
for falciparum malaria
(various regimens)
1- 4 days according to drug 6-36 mths All not re-exposed improved
or fully recovered
Puente et al. 2001 [83] Spain 14 Africans (13 from E. Guinea,
1 from Cameroon)
Quinine standard dose for
1 wk then CLQ
3- 9 mths (mean = 4.3 mths) 3 - 9 mths (mean = 4.3
mths)
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The Italian study (Table 3) [43] (57 patients, mostly
European Caucasians, of which 28 with an incomplete
‘early’ stage HMS) confirmed the efficacy of short treat-
ment in absence of re-exposure, and showed 100% im-
provement at follow-up (six to 36 months after therapy).
The remaining four papers are case reports. Two of them
reported a global improvement at follow-up visits, two and
24 months after treatment, respectively [17,82]: one used
quinine plus doxycycline and the other one mefloquine.
Conversely, one case was described with no improvement
eight months after a three-day course of atovaquone-
proguanil [46].
The prospective study in Spain (Table 3) [19], that was
conducted on 14 African subjects, besides using a short
course of anti-malarial treatment just as in the Belgian
and Italian studies referred to above [42,43], also added
weekly chloroquine for a longer period, ranging from
three to nine months, basically obtaining the same clin-
ical results (in those not re-exposed) as in the two previ-
ous studies. Most other authors opted for long-term
treatment following, in some cases only, a short anti-
malarial course [84,85]. The duration of therapy varied
from one [46] to 12 months or until recovery [83,86].
Intermittent therapy was also used, with quinine [45] or
with chloroquine plus proguanil [87].
The most common prescription, just as in endemic
countries, was chloroquine alone [54,83,85,88], or in com-
bination with doxycycline [46], with proguanil [42,85,89]
or with primaquine [90], or preceded by a short course of
quinine [19,83,88] or halofantrine [83]. Other regimens
used for long-term treatment were proguanil [67,85,86],
mefloquine [91] or quinine plus doxycycline [17].
All patients with no further exposure and with avail-
able follow-up data improved. It is not clear whether a
mere withdrawal of exposure, without treatment, could
be sufficient to obtain HMS resolution: only a few case
reports debate on this aspect. One described the persist-
ence of HMS in a eight years old Caucasian boy, who
had been on chloroquine prophylaxis while in Africa,
after an 18-month stay in Europe [91]. Another case of
HMS was diagnosed in an Ethiopian immigrant after a 19-
month stay in Israel [38]. On the contrary, a spontaneous
resolution of the syndrome was reported in a Guinean pa-
tient after two months of residence in a malaria-free area,
with a regression of the spleen size from 20 cm to 3-4 cm
below the costal margin and a normalization of all labora-
tory findings [92]. The main results of the three case series
described in Europe with more than ten patients are sum-
marized in Table 3.
Splenectomy
Splenectomy in HMS is generally suggested for patients
with huge splenomegaly and disabling symptoms, whodo not respond to medical treatments [29,93]. One study
analysing short- and long-term outcome of splenectomy
reported a peri-operative mortality rate of about 31% ris-
ing to 39% at long-term (41-74 months) follow-up [94].
The most frequent peri-operative complications de-
scribed were major bleeding and infections. The latter
were the main cause of death in the following months.
Most surviving patients improved. However, the liver
tended to progressively enlarge, probably related to per-
sistence of the antigenic stimulus [95]. In non-endemic
areas, therapeutic splenectomy has been reported in
Venezuela, Sri-Lanka, Hong Kong [30,39,41] and the
USA (for haemolytic anaemia complicating HMS) [40].
Discussion
The literature available on HMS consists of some case
reports and a few case series. Parameters considered by
different authors are often heterogeneous and hardly
comparable. However some key points are identifiable.
First of all, HMS should be taken into consideration in
all patients with splenomegaly living/having lived in mal-
arious areas. Strict adherence to Fakunle’s criteria is
questionable. Some authors observed that cases not
completely fulfilling the criteria can subsequently evolve
into the full-blown, ‘classical’ HMS [42,43], thus repre-
senting an early stage of the syndrome. Considering the
high fatality rate of this condition, if left untreated, as
well as the wide availability of effective anti-malarial
drugs, it seems appropriate to treat HMS even in case
the classical triad of splenomegaly, raised IgM and anti-
malarial antibodies is only partially satisfied. Clearly, in-
vestigations of other possible causes of splenomegaly
should be carried out, in particular, but not limited to,
considering lymphoproliferative disorders.
The treatments administered have been heterogeneous
and do not permit recommending a first choice regimen
yet, considering the lack of randomized clinical trials.
However, for patients who move from endemic to non-
endemic areas, there is circumstantial evidence support-
ing the fact that an adequate short-course treatment is
effective [42,43]. This contrasts with the more common
choice of a long-term anti-malarial course in these cases,
too, which is the classical approach that has been sug-
gested and followed for decades. It reflects the view that
the syndrome tends to evolve even though malaria para-
sites are no longer present in blood. This particular as-
pect was described in a study showing a progressive
enlargement of the liver after splenectomy in a patient
with negative thick blood films. This occurrence was at-
tributed to persistence of the underlying stimulus to
reticulo-endothelial system [95]. According to the most
cited authors [2], the absence of parasitaemia is one of
the diagnostic criteria. This view does not hold any lon-
ger. On the one hand, recent reports showed that more
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malarial infection in HMS patients [17]. This suggests that
Plasmodium is present, albeit often at sub-microscopic
parasite density. On the other hand, the full response to a
short course of anti-malarial therapy indicates that the
eradication of the infection is usually sufficient to cure
HMS [28,42,43]. Therefore, the presence of Plasmodium in
blood is necessary for a further development of the syn-
drome. This is also suggested by the unusual case of HMS
reported above [67]: a child who still had circulating
Plasmodium eight months after her last short-term visit to
a malaria-endemic country.
Conclusion
Lifelong effective malaria prophylaxis or intermittent
treatments are probably necessary for those who remain
exposed to malaria transmission. Chloroquine seems to
still be partially effective, even if P. falciparum resistance
has developed. Possibly this regimen acts not only as an
anti-malarial, but also as an immunomodulating and im-
munosuppressant therapy [47,96], as it is suggested by
the regression of the spleen size even in patients with
lymphoproliferative disorders [60]. The choice of the
drug should consider the local pattern of P. falciparum
drug susceptibility, as well as the availability and cost
of the different regimens. Splenectomy is potentially
associated with high mortality, therefore it should be
strictly limited to cases that do not respond to medical
treatment [94,97].
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